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Organic anion transporting polypeptide
Phosphorylation
RecyclingOrganic anion-transporting polypeptides aremembers of the solute carrier (SLC) family and key determinants for
the transmembrane transport of a wide variety of compounds. OATP1B1 is predominantly expressed at the
basolateral membrane of human hepatocytes and play an important role in drug clearance from the body. It
has been demonstrated to be responsible for the hepatic uptake of various drugs. Computer-based hydropathy
analysis predicted several putative phosphorylation sites at the amino and carboxyl termini and at intracellular
loop 3 of OATP family members. Therefore, their transport functions may be regulated by phosphorylation.
Previous studies have demonstrated that uptake function of OATP2B1 and OATP1A2 is regulated by protein
kinase C (PKC). In the present study, we treated HEK293 cells stably expressing OATP1B1 with different PKC
modulators and measured their transport activity for prototypic substrate estrone-3-sulfate. It was found that
OATP1B1 uptake function was reduced upon PKC activation. Further studies indicated that PKC may affect
OATP1B1 activity through regulation of the cell surface protein level. Moreover, we found out that PKC activator
phorbol 12-myristate 13-acetate (PMA) not only affects the internalization of OATP1B1 but its recycling as well.
Immunocytochemistry analysis revealed that internalized OATP1B1 co-localized with early and recycling
endosomalmarkers and the co-localization ofOATP1B1with recycling endosome is dependent on PKC activation.
Taken together, our present study demonstrated that PKC regulates the function of OATP1B1 by affecting inter-
nalization and recycling of the transporter protein.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Organic anion-transporting polypeptides (human OATPs; other
species Oatps; gene family SLC21/SLCO) belong to the solute carrier
(SLC) family and are responsible for the transport of a wide range of
structurally independent compounds [1]. So far there are 12 members
of the human OATP family: OATP1A2, 1B1, 1B3, 1B7, 1C1, 2A1, 2B1,
3A1, 4A1, 4C1, 5A1 and 6A1 [2–5], though OATP1B7 is considered as
non-functional so far and SLCO1B7 was proposed as a pseudogene [6].
Substrates of OATPs are usually anionic chemicals that contain steroidal
or peptide structural backbones [1]. Endogenous compounds such as
bile acids, hormones and their conjugates are substrates of OATPs. In
addition, pharmaceuticals including HMG-CoA reductase inhibitors
(statins), angiotensin-converting enzyme inhibitors, angiotensin recep-
tor II antagonists, cardiac glycosides, anti-tumor drugs such as metho-
trexate [7,8] and antibiotics such as ﬂuoroquinolones [9] have beenfosuccinimidyl 2-(biotinamido)-
ng polypeptide; PBS, phosphate-
+86 20 8528 2180.demonstrated to be transported by OATPs. OATPs are expressed at var-
ious epithelial barriers including intestinal epithelial cells, hepatocytes,
renal tubular cells, and at the blood–brain barriers [10]. Recently
it was also proposed that OATPs are localized in the pulmonary tissue
[10]. Because of their ubiquitous distribution and capability of
transporting a large variety of compounds, OATPs are responsible for
many drug–drug interactions [11,12]. OATP family member OATP1B1
is the major OATP located at the basolateral membrane of human
hepatocytes and plays a major, clinically important role in the hepatic
uptake of numerous drugs [7,13,14].
According to computer-based hydropathy analysis, OATP family
members are predicted to share several common structural features in-
cluding putative phosphorylation locations at the amino and carboxyl
termini of the protein and at intracellular loop 3 [15]. Studies on rat
Oatps have demonstrated that transport function of Oatp1 (Oatp1a1)
and Oatp2 (Oatp1a4) may be regulated by protein kinase C (PKC)
[16,17]. It was also shown that rat Oatp1a1 can be singly or doubly
phosphorylated at serine or threonine residues in the C-terminal se-
quence SSATDHT (amino acid 634–640) and that in the case of doubly
phosphorylation, it is an ordered process, in which phosphorylation at
Ser634 precedes that at Ser635 [18]. Further studies revealed that
phosphorylation at these two positions plays a critical role for the fast
regulation of rat Oatp1a1 distribution between the plasma membrane
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ulation of OATP2B1 demonstrated that OATP2B1 function is regulated
by a PKC-mediated and clathrin-dependent pathway. OATP2B1 was
internalized after being phosphorylated and targeted to lysosome for
degradation. However, unlike the rat Oatp1a1, simultaneous mutation
of 17 predicted phosphorylation sites to alanine did not alter response
of OATP2B1 to PKC activation, implicating that phosphorylation at
these sites may not be required for OATP2B1 internalization [20].
Similarly, function and cell membrane expression of OATP1A2 was
found to be affected by PKC regulators. It was demonstrated that these
changes are due to phosphorylation related clathrine-dependent inter-
nalization process as well [21].
In thepresent study,we investigated the effect of PKCmodulators on
the uptake function of OATP1B1 and found out that OATP1B1 transport
function is regulated by PKC, the action of which leads to accelerated
internalization and reduced recycling of the transporter protein.
2. Materials and methods
2.1. Materials
[3H]estrone-3-sulfate (ES) was purchased from PerkinElmer Life
Sciences (Waltham, MA). Sulfosuccinimidyl 2-(biotinamido)-ethyl-1,
3-dithiopropionate (NHS-SS-biotin) and streptavidin-agarose beads
were from Thermo Fisher Scientiﬁc (Waltham, MA). Anti-HA and anti-
EEA1 antibodies were from Cell Signaling Technology (Danvers, MA).
Anti-Rab11 and anti-OATP1B1 antibodies were purchased from Abcam
(Cambridge, UK). All other reagents were purchased from Sigma (St.
Louis, MO) except otherwise stated.
2.2. Cell culture and establishment of HEK293 cells stably expressing
SLCO1B1
HEK293 cellswere grown at 37 °C and 5%CO2 inDulbecco'smodiﬁed
Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (Invitrogen). Conﬂuent cells in 6-well plate were
transfected with pReceiverM07 vector, pReceiver M07 vector contain-
ing the SLCO1B1 cDNA and 3-HA tags at the C-terminus (designated as
OATP1B1-HA) or pReceiver M03 vector and pReceiver M03 vector con-
taining the SLCO1B1 cDNA taggedwith green ﬂuorescence protein (GFP)
at the C-terminus (designated as OATP1B1-GFP) (Genecopoeia, Rock-
ville, MD) using LipofectAMINE 2000 reagent (Invitrogen). Seventy-
two hours after transfection, the transfection medium was replaced
with DMEM containing 0.6 mg/ml of G418 for selection. Ten days after
antibiotic selection, single colonies were picked up and transferred to
60 mm cell culture dishes for further propagation.
2.3. Uptake assay, cell surface biotinylation and western blot
Cells in 48-well plates were used for transport measurement as
described previously [22] with minor modiﬁcations. Brieﬂy, cells were
incubated with uptake solution containing [3H]ES at 37 °C for 2 min
(1 min for kinetic analysis) and uptake was stopped by addition of
ice-cold phosphate-buffered saline (PBS) solution. Cells were then
washed with cold PBS and solubilized in 0.2 N NaOH. The radioactivity
of the cell lysate was measured with a liquid scintillation counter
Triathler-Hidex (Hidex, Turku, Finland). Cell surface expression of
OATP1B1 was examined with the membrane-impermeable biotinyl-
ation reagent NHS-SS-biotin using a method described previously [22].
Cryopreserved human hepatocytes were purchased from
BioreclamationIVT (Baltimore, MD) and cells were thawed following
the manufacturer's instructions. Viability of the cells was evaluated
with trypan blue staining and was determined as more than 70%.
2.6 × 106 cells were re-suspended in 500 μl of growing medium
(DMEM with 5% FBS, 0.5% (w/v) HEPES, 0.4% (w/v) bovine serum
albumin and 0.04% (w/v) D-glucose, pH 7.4) containing 0.05% DMSOor 10 μM PMA. Thirty minutes after PMA treatment, hepatocytes were
washed three times with ice-cold PBS, biotinylated, lysed and detected
with anti-OATP1B1 antibody (in 1:500 dilution, Abcam, Cambridge,
UK).
2.4. Internalization assay
Analysis for constitutive and PKC-mediated internalization was
performed as described by Zhang et al. [23] with minor modiﬁcations.
Brieﬂy, equal number of cells (2.5×106 cells per well) expressing
OATP1B1 was seeded in 6-well plates. Twenty hours after seeding,
monolayer cells were labeled with 1.0 mg/ml NHS-SS-biotin for
30min. One set of cells was kept at 4 °C as a pre-internalization control,
while other cells were rapidly warmed up to 37 °C by pre-warmed PBS
with or without PMA (10 μM). Internalization was stopped at 15 and
30min and residual biotin on the cell surfacewas stripped by incubating
cells with 50 mM sodium 2-mercaptoethanesulfonate (MesNa) in NT
buffer (150 mM NaCl, 1 mM EDTA, 0.2% bovine serum albumin,
20 mM Tris, pH 8.6). The cells were then dissolved on ice for 1 h in
400 μl of RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% NP-40,
protease inhibitors phenylmethylsulfonylﬂuoride, 200 μg/ml, leupeptin,
3 μg/ml, pH 7.4). After cell debris was removed by centrifugation, thirty
microliters of cell lysate was transferred to a clean eppendorf tube
and would be used as an OATP1B1 total protein control. Streptavidin-
agarose beads were added to the remaining cell lysate to bind the
biotin-labeled proteins. Protein was released and denatured in 4×
Laemmli buffer and loaded onto a 7.5% SDS-polyacrylamide electropho-
resis gel and then transferred electrophoretically to a polyvinylidene
diﬂuoride membrane (Millipore, Billerica, MA). OATP1B1 was detected
with anti-HA antibody.
2.5. Recycling assay
The procedure of Zhang et al. [23] was followed with minor modiﬁ-
cations for OATP1B1 recycling experiments. OATP1B1-expressing
cells were ﬁrst biotinylated with 1.0 mg/ml NHS-SS-biotin at 4 °C for
30 min and then replaced with new NHS-SS-biotin (1.0 mg/ml, 4 °C
for recycling control plate and 37 °C for recycling plate). Biotinylation
was stopped at 15 min and 30min and biotinylated proteins were sub-
sequently pulled-down by streptavidin beads and analyzed as described
above.
2.6. Immunoﬂuorescence analysis of cells expressing OATP1B1
HEK293 cells stably expressing OATP1B1-GFP were treated with
PMA for 30 min, then washed three times with PBS and ﬁxed with 4%
paraformaldehyde for 15 min at room temperature. The ﬁxed cells
were permeabilized with 0.02% Tween-20 for 5 min, washed with
PBS and incubated with PBS containing 1% bovine serum albumin for
1 h at room temperature. Primary antibodies (dilution according
to manufacturer's recommendation) in the same medium was then
added and incubated overnight at 4 °C. The cells were washed, and
bound primary antibodies were detected by reaction with Alexa Fluor
555 goat anti-rabbit IgG antibody diluted 1:1000 (Cell Signaling Tech-
nology) for 1 h. Cells were thoroughly washed and the cover glasses
were mounted in Fluoromount mounting medium. Samples were
examined using a Zeiss LSM 780 confocal microscope (Carl Zeiss,
Oberkochen, Germany).
2.7. Inhibition of clathrin- or caveolin-mediated internalization
To block clathrin-dependent endocytosis, cells were pre-incubated
with hypertonic medium (0.45 M sucrose in culture medium) for
30 min or with 10 mM acetic acid in culture medium for 10 min as
described before [19]. To disrupt caveolin-mediated endocytosis, cells
were pre-incubated with 200 μM of genistein in the culture medium
Fig. 1.HEK293 cells stably expressing OATP1B1. A. Cell surface expression of OATP1B1. Cells were biotinylated with NHS-SS-biotin and precipitated with streptavidin beads, separated by
SDS-PAGE, followed bywestern blotting with anti-HA antibody. Integrinwas used as loading control. B. Immunocytochemistry analysis of OATP1B1. Cells were ﬁxedwith 4% paraformal-
dehyde, permeabilized with 0.1% Triton X-100 and incubated with anti-HA antibody (1:300 dilution) overnight at 4 °C. Bound primary antibodies were detected by reaction with Alexa
Fluor 488 goat anti-mouse diluted 1:1000 for 1 h. C. Kinetic analysis of estrone-3-sulfate uptake by OATP1B1. Uptake of ES was measured at concentrations range from 0.01 to 50 μM at
37 °C for 1 min. Net uptake was obtained by subtracting the uptake of cells with empty vector from cells expressing OATP1B1. The results represent data from three experiments, with
duplicate measurements for each sample. The results shown are means ± S.E. (n = 3). Kinetic values were obtained using the Eadie–Hofstee transformation.
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10 μM PMA in the continuous presence of the inhibitors for 15 min.
Internalization assay was then performed as described above.
Statistical analysis—Data statistical analysis was carried out using
one-way analysis of variance. Differences between means are regarded
as signiﬁcant if p b 0.05.
3. Results
3.1. OATP1B1 uptake function was down-regulated by PKC activation
To investigate the regulatory effect of PKC on OATP1B1 uptake
function, we ﬁrst generated a HEK293 cell line that stably expressed
OATP1B1 (with 3-HA tags at its C-terminus and designated as
OATP1B1-HA). As shown in Fig. 1A, cells in which SLCO1B1 was stably
integrated exhibited a ~95 kD band for cell surface protein expression
analysis. Such a signal was not detected in the vector-transfected
cells. Immunocytochemical analysis also showed that cells stably
expressing OATP1B1-HA exhibited ﬂuorescence signals along cell sur-
face (Fig. 1B). The linear ranges for uptake of 0.01 μM and 50 μM
estrone-3-sulfate (ES) were 5 min and 3 min, respectively (data not
shown). Therefore, kinetic analysis of OATP1B1 was performed within
1 min period. It was demonstrated that OATP1B1-expressing cells
transported prototypic substrate estrone-3-sulfate (ES) and displayed
a biphasic saturation kinetics with Km values of 0.10 ± 0.03 μM and
53.0 ± 14.8 μM (Fig. 1C), which is consistent with previous reports
[13,26,27].
Since previous reports demonstrated that transport function of
human OATPs [20,21] was suppressed by PKC activation, we treated
the OATP1B1-expressed cells with PKC activator phorbol 12-myristate
13-acetate (PMA) and PKC inhibitor Gö6983 to see whether such a
regulatory effect also occurred in OATP1B1. As shown in Fig. 2A,
PMA treatment dramatically reduced OATP1B1-mediated ES uptake
(49.3 ± 6.3% of the untreated control). On the other hand, Gö6983,
which is a PKC inhibitor and inhibited several PKC isozymes including
PKCα, PKCβ and PKCγ (IC50 b 10 nM), PKCδ (IC50 = 10 nM), PKCζ
(IC50 = 60 nM) and PKCμ (IC50 = 20 μM), slightly but signiﬁcantly in-
crease ES transport activity of OATP1B1 (144 ± 23% of the untreated
control). Moreover, the down-regulation of OATP1B1 by PMA was
completely blocked by co-treatment with Gö6983. Further analysis
showed that 30 min treatment of PMA resulted in a reduced Vmax for
both low and high concentrations ES uptake (9.2 ± 2.9 pmol/mgprotein/min in PMA treated cells vs 18.9 ± 4.8 pmol/mg pro-
tein/min in DMSO treated cells, and 724 ± 7 pmol/mg protein/
min in PMA treated cells vs 1218 ± 144 pmol/mg protein/min
in DMSO treated cells for low and high concentrations ES uptake,
respectively) but no signiﬁcant change in Km values (0.16± 0.01 μM in
PMA treated cells vs 0.14 ± 0.03 μM in DMSO treated cells, and
31.5 ± 1.7 uM in PMA treated cells vs 38.7 ± 5.9 uM in DMSO treated
cells for low and high concentrations ES uptake, respectively)
(Fig. 2B).3.2. Conventional PKC isoforms are involved in reduction of OATP1B1 trans-
port activity
Since Gö6983 is a PKC inhibitor that is capable of suppressing several
PKC isozymes and with the concentration applied above (20 μM), its
effect on PMA-treated cells may not be speciﬁc to one PKC isoform,
we next applied different concentrations of Gö6983 as well as different
PKC isozyme speciﬁc inhibitors to analyze the possible PKC isoforms in-
volved in regulation of OATP1B1 transport function. At a concentration
that corresponds to IC50 of PKCα and PKCβ (b10 nM), Gö6983 signiﬁ-
cantly blocked the inhibition effect of PMA. Interestingly, when concen-
tration of the inhibitors was increased to 10 nM and 60 nM that
correspond to the IC50 of PKCδ and PKCζ, respectively, no more induc-
tion effect was observed. The activity of OATP1B1-mediated ES function
was fully recovered when cells were co-treated with 20 μM Gö6983
(Fig. 3A). Such an effect may be due to two possibilities. The higher
concentration of Gö6983 may result in a high enough concentration
within cells to totally block the inhibitory effect exerted by PMA or
PKCμ (IC50 = 20 μM) is also involved in such an effect. Further analysis
demonstrated that Gö6976, which is a speciﬁc inhibitor for PKCα
(IC50 = 2.3 nM) and β1 (IC50 = 6.2 nM) isozymes, signiﬁcantly
increased uptake of OATP1B1-expressed cells treated with PMA. On
the other hand, neither gramine (a selective PKCδ down-regulator)
[28] nor CID755673 (a selective inhibitor of PKCμ (PKD1, PKD2
and PKD3)) [29] could attenuate suppressive effect of PMA treat-
ment (Fig. 3B). The speciﬁcity and effectiveness of these two inhibi-
tors were validated by their capability of suppressing the activation
effect of PKCδ and PKCμ by PMA (Supp. Fig. 1). These results implicat-
ed that PKC conventional isozymes α and β1 are involved in regula-
tory process of OATP1B1, while PKCδ and PKCμ do not participate in
such an effect.
Fig. 2. PKC modulators affected OATP1B1 transport function. A. Response of OATP1B1-expressed cells to PMA treatment. Cells were treated with 10 μM PMA or 20 μM Gö6983 alone or
20 μM Gö6983 together with 10 μM PMA for 30 min before subjected to uptake assay. Cells treated with 0.05% DMSO were used as control. Uptake of 50 nM ES was measured at 37 °C
for 2 min. Transport activity was expressed as a percentage of the uptake measured in control. Different letters indicated signiﬁcant difference among treatments for ES uptake
(p b 0.05). B. Concentration-dependent transport function of OATP1B1-expressing cells treated with PMA. Cells were treated with 10 μM PMA for 30 min before uptake reaction. Uptake
of ES wasmeasured at concentrations range from 0.01 to 1 μM (upper panel) or from 0.5 to 20 μM (lower panel) at 37 °C for 1 min. Net uptake was obtained by subtracting the uptake of
cells with empty vector from cells expressing OATP1B1. All the results represent data from three experiments, with duplicate measurements for each sample. The results shown are
means ± S.E. (n = 3). Kinetic values were obtained using the Eadie–Hofstee transformation.
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expression
A decreased Vmax for ES uptake in response to PKC activation by
PMAmay be due to a decrease in transporter density at the cytoplasmic
membrane or a decrease in transport turnover rates [30]. Therefore, we
examined the cell surface level of OATP1B1 with or without PMA treat-
ment. We found that treatment of OATP1B1-expressing cells with PMA
resulted in a reduction of OATP1B1 at the cell surface and an increase of
the transporter protein in intracellular compartment (Fig. 4A). Total ex-
pression of OATP1B1 was not signiﬁcantly altered after PMA treatment,
indicating the reduction of OATP1B1 on cell surface was not due to
protein degradation (Fig. 4A). A similar effect was observed in human
hepatocytes. After PMA treatment, cell surface level of OATP1B1 was
reduced, suggesting the PKC regulatory effect also occurs in vivo
(Fig. 4B).3.4. PKC modulates OATP1B1 internalization and recycling
Since activation of PKC seemed to accelerate the re-distribution of
OATP1B1 from cell surface to intracellular regions, we next wanted toFig. 3. The effect of PKC inhibitors on ES uptake function. A. Uptake of estrone-3-sulfate by OATP
of cells treated with different PKC inhibitors. Cells were treated with 10 μM PMA and different
50 nMESwasmeasured at 37 °C for 2min. Transport activity of cells treatedwith PKCmodulato
The results represent data from three experiments, with duplicate measurements for each sa
difference among treatments for ES uptake (p b 0.05).investigate whether PKC affect internalization and/or recycling of
OATP1B1. After cells were biotinylated with cell-impermeable biotinyl-
ation reagent NHS-SS-biotin at 4 °C, which is a trafﬁcking-impermissive
condition, for 30 min, the biotinylated cells were promptly warmed to
trafﬁcking-permissive condition (37 °C) to allow internalization to
occur. The biotin on labeled proteins that still remained on cell surface
was strippedoff at indicated timepointswithMesNa, leaving only inter-
nalized proteins retained the biotin that was needed to be pulled down
by streptavidin-agrose beads [23]. Our results showed that a constitu-
tive internalization of OATP1B1 occurred (Fig. 5) while the treatment
of PMA greatly accelerated such a process, suggesting activation of
PKC induced the internalization of OATP1B1.
In order to see whether OATP1B1 constitutively recycles back to cell
surface andwhether PMA exert an effect on such a process, we incubat-
ed intact OATP1B1-expressing cells with 1.0 mg/ml NHS-SS-biotin at
4 °C for 30min to completely label the cell surface pool of the transport-
er protein. Then one set of cells continue to biotinylate at 4 °Cwhile cells
in the duplicate plate were promptly warmed to 37 °C and continuously
biotinylated at 37 °C [31,32]. As revealed in Fig. 6, cells thatwere labeled
under trafﬁcking-permissive conditions (37 °C) showed stronger signal
compared with the ones that were kept at trafﬁcking-impermissive
conditions (4 °C) [23]. Interestingly, PMA treatment signiﬁcantly1B1-expressing cells treatedwith different concentrations of Gö6983. B. Transport function
concentrations of PKC inhibitors as indicated for 30 min before uptake reaction. Uptake of
rswas compared to that of DMSO-treated cells and presented as percentage of the control.
mple. The results shown are means ± S.E. (n = 3). Different letters indicated signiﬁcant
Fig. 4. Cell surface expression of OATP1B1 after PMA treatment. A. Cells were ﬁrst treated for 30min in the presence of DMSO or 10 μMPMA and then biotinylatedwith NHS-SS-biotin and
precipitated with streptavidin beads, separated by SDS-PAGE, followed by western blotting with anti-HA antibody. Thirty microliters of cell lysate was taken out before and after the in-
cubation with streptavidin beads as the total and intracellular OATP1B1 protein samples. Left panel, representative blot of OATP1B1 expression without or with PMA treatment. Right
panel, band intensity of OATP1B1 was quantiﬁed relative to that of the DMSO treated control. The results shown are means ± S.E. (n = 3). Asterisk indicated signiﬁcant difference com-
pared with DMSO-treated control (p b 0.05). B. Human hepatocytes were treated for 30 min in the presence of DMSO or 10 μM PMA, then biotinylated and detected with anti-OATP1B1
antibody.
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tion of PKC also down-regulates OATP1B1 recycling back to the plasma
membrane (Fig. 6).
3.5. Internalized OATP1B1 co-localizes with early and recycling endosomal
markers
It was demonstrated that cell surface amount of dopamine trans-
porter (DAT) was decreased upon PKC activation and that the internal-
ized DAT diverges to the recycling endocytic pathway instead of the
degradative pathway [30]. When we analyzed the distribution of
OATP1B1 after PMA treatment, it was found out that a substantial
amount of OATP1B1 is located within the intracellular compartments
upon PMA treatment (Fig. 7). Signals of the internalized OATP1B1 co-
localized with early endosomal markers EEA1 and the amount of
OATP1B1 co-localized with EEA1 increased signiﬁcantly upon PMA
treatment. However, it both cases, there were a fair number of
OATP1B1 separated from EEA1, indicating that certain amount of inter-
nalized OATP1B1 had left the early endosome (Fig. 7A). It was reported
that PKC activation led to translocation of membrane proteins such as
epidermal growth factor receptor to the pericentrion [33], we therefore
performed co-localization analysis of OATP1B1 and Rab11, a marker of
recycling endosome [34]. As shown in Fig. 7B, in the absence of PMA,
OATP1B1-GFP was mostly localized to the cell surface membrane and
separated from Rab11. When cells were stimulated with PMA for
30 min, internalized OATP1B1-GFP became more clustered and co-
localized with Rab11. Such a sequestration was dependent on PKCactivation because when Gö6983 was added together with PMA,
OATP1B1was dispersed and localizedmostly on the plasmamembrane.
These results suggested that OATP1B1 internalized upon PMA treat-
ment was destined to the early and recycling endosome.
OATP2B1 and OATP1A2 have been demonstrated to be regulated
by PKC in a clathrin-dependent and caveolin-independent pathway
[20,21]. Similarwith OATP2B1 andOATP1B1,we also found out that hy-
pertonic sucrose and acidiﬁcation of the cytoplasm, two treatments that
were found to prevent clathrin-dependent protein internalization [21],
attenuated PMA-induced OATP1B1 trafﬁcking (Fig. 8), suggesting that
OATP1B1 also trafﬁcks in a clathrin-dependent manner. On the other
hand, cells pretreated with genistein, a blocker of caveolae-mediated
endocytosis [24,25] did not affect cell surface expression of the trans-
porter protein upon PMA treatment. To validate the effectiveness of
these blockers, we also performed internalization experiments with
transferrin receptor, a well-known membrane protein that undergoes
clathrin-dependent [35] endocytosis, and transforming growth factor
β receptor (TGF receptor), which are known to internalize in both
clathrin- and caveolae-mediated pathways [36] (Supp. Fig. 2).
4. Discussion
As an important post-translational modiﬁcation, phosphorylation
has been demonstrated to regulate the location and/or activity of
various carrier proteins [20]. Previous studies of OATP showed that
the transport function of OATP2B1 [20] and OATP1A2 [21] as well as
rat Oatp1a1 [18] is regulated by this post-translational modiﬁcation. In
Fig. 5. PMA induced OATP1B1 internalization. Cells expressing OATP1B1 was ﬁrst labeled with 1.0 mg/ml NHS-SS-biotin for 30 min. Internalization was initiated by rapidly warmed up
cells to 37 °C by pre-warmed PBS with or without PMA (10 μM). Residual biotin on the cell surface was stripped off by 50 mMMesNa after different internalization periods as indicated.
Cellswere then precipitatedwith streptavidin beads, separated by SDS-PAGE, followed bywestern blottingwith anti-HA antibody. Representative blotwas shown (upper panel) and band
intensity of different treatment was qualiﬁed (lower panel). The results shown are means ± S.E. (n = 3).
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port function of another OATP family member OATP1B1.
OATP1B1 is a critical uptake transporter that participates in the
hepatic uptake of a wide range of organic anions, including bile salts,
hormones, peptides, and a broad range of drugs that have various chem-
ical structures and clinical uses [2,14]. The HEK293 cells expressing
OATP1B1-HA generated in the present study has a transport kinetics
of ES that is in good agreement with previous reports [13,26,27],
suggesting the OATP1B1-expressing cells was a reliable system for
functional regulation study. Similar to other OATP family members,
the uptake function of OATP1B1 was altered by treatment of PKC mod-
ulators.WhenOATP1B1-expressing cells were treatedwith inhibitors of
different PKC isozymes, only those that inhibit conventional PKCs
(PKCα and PKCβ) could attenuate the inhibitory effect exerted by
PMA, suggesting the involvement of conventional PKCs in the regulation
of OATP1B1 uptake. Further analysis revealed that the reduced uptake
function upon PMA treatment was due to reduced Vmax, which was
accounted for by a decreased transporter protein level on the cell
surface. The effect of PMA was reversible. Cell surface expression of
OATP1B1 was recovered over time after termination of PMA treatment
(data not shown). The effect PMA on OATP1B1 was also observed in
human hepatocytes. After PMA treatment, OATP1B1 level on plasma
membrane was reduced, suggesting such a regulatory effect occurs
in vivo as well.
Studies have already shown that transport activity of both OATP2B1
and OATP1A2 is down-regulated by PKC activator PMA. In OATP2B1,
the transport function reductionwas due to internalization of the trans-
porter protein that in turn is targeted to the lysosomal degradation
pathway [20]; while the PMA treatment of OATP1A2 led to accelerated
internalization but had no effect on its recycling [21]. In both cases,internalization of the transporter proteins is clathrin-dependent.
These results suggested that though PKC is involved in the internaliza-
tion of OATP family members, transporter proteins retreated from
the plasma membrane may go through different pathways. Indeed,
our present data indicated that the reduced surface expression of
OATP1B1 was a result of both increased internalization and suppressed
recycling upon PMA treatment. Unlike OATP2B1, PKC-mediated regula-
tion of OATP1B1 did not lead to degradation of the transporter protein,
because the amount of OATP1B1was comparable to that of the untreat-
ed control till 2 h after PMA treatment (data not shown). Moreover,
immunocytochemistry analysis of PMA-treated cells showed that
signiﬁcantly increased amount of OATP1B1 was sequestered to a
juxtanuclear region of the cells, in which it was co-localized with
recycling endosomal marker Rab11. On the other hand, when PKC
inhibitor was added together with PMA, the sequestered effect was
attenuated. OATP1B1 was again accumulated along the plasma mem-
brane and separated from Rab11. These results implicated that upon
PKC activation, the internalized OATP1B1 was retained within the
recycling endosomes. Since the internalization of OATP1B1 was sensi-
tive to hypertonic sucrose and acidiﬁcation of the cytoplasm, two
treatments that were found to prevent clathrin-dependent protein in-
ternalization and resistant to caveolae-mediated endocytosis blocker
genistein, the transporter also internalized in a clathrin-dependent
pathway, similar to that of OATP2B1 and OATP1A2.
In addition to the OATP family members, activation of PKC has been
demonstrated to inﬂuence transport process of different drug trans-
porters such as rat organic cation transporter (rOCT1) [37], rat bile salt
export pump (Bsep, Abcc11), multidrug resistance-associated protein
2 (Mrp2, Abcc2) [38], and human organic anion transporter (OAT1)
[23]. Since PKC is related with the occurrence of many diseases, the
Fig. 6. PMA affected OATP1B1 recycling. OATP1B1-expressing cells were biotinylated with 1.0 mg/ml NHS-SS-biotin for 30 min and then replaced with new NHS-SS-biotin, incubated at
4 °C for control and 37 °C for recycling. Biotinylationwas stopped at 15min and30min by100mMglycine and biotinylated proteinswere pull-downed by streptavidin beads, separated by
SDS-PAGE, followed bywestern blotting with anti-HA antibody. Representative blot was shown (upper panel) and band intensity of different treatment was qualiﬁed (lower panel). The
results shown are means ± S.E. (n = 3). Asterisk indicated signiﬁcant difference compared with DMSO-treated control (p b 0.05).
Fig. 7. Internalized OATP1B1 co-localizedwith early and recycling endosomal markers. A. OATP1B1 co-localizedwith EEA1 after PMA treatment. B. OATP1B1-colocalizedwith Rab11 upon
PMA treatment. Cells expressing OATP1B1-GFP was treatedwith DMSO or 10 μMPMAor 20 μMGö6983 together with PMA for 30min and then ﬁxedwith 4% paraformaldehyde, perme-
abilized with 0.02% Tween-20 and incubated with 1% bovine serum albumin for 1 h at room temperature. Primary antibodies (anti-EEA1 1:100, Rab11 1:400) in the samemediumwere
then added and incubated overnight at 4 °C. Bound primary antibodies were detected by reaction with Alexa Fluor 555 goat anti-rabbit IgG antibody and examined using a Zeiss LSM 780
confocal microscope.
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Fig. 8. PMA induced-OATP1B1 trafﬁcking is clathrine-dependent. OATP1B1-expressed cells were pre-incubated with 0.45 M sucrose for 30 min or with 10 mM acetic acid for 10 min or
with 200 μM of genistein for 30 min. Cells were then treated either with DMSO (0.05%) or 10 μM PMA in the continuous presence of the inhibitors for 15 min. Internalization assay
was then performed as described in Fig. 5.
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lation and hence treatment outcome [20]. At the protein level, OATP1B1
is found only in the liver, where it has been localized to the basolateral
membrane of hepatocytes [39]. However, in recent years, studies have
found that under pathological conditions (inﬂammation and cancer),
such a restricted expression pattern of OATP1B1 can no longer bemain-
tained and expression of OATP1B1 had been reported in prostate cancer
[40] and pancreatic cancer [41]. In addition to statins and antibiotics, an-
ticancer drugs such as methotrexate, docetaxel, irinotecan metabolite
SN38, camptothecin derivatives gimatecan and BNP1350, the cyclin
dependent kinase inhibitor avopiridol, and the cisplatin derivatives
Bamet-R2 [cis-diamminechloro-cholylglycinate-platinum(II)] and
Bamet-UD2 [cis-diamminebisursodeoxy-cholate-platinum(II)] are
transported by OATP1B1, which implicates that this transporter protein
may play an important role in the intracellular accumulation of these
anti-neoplastic drugs [42]. The redistribution of OATP1B1 from plasma
membrane into intracellular region upon PKC activation, which in turn
leads to reduced function of the transporter may therefore have impact
on the uptake of quite a few therapeutic agents.
Our current study demonstrated that OATP1B1 uptake function is
regulated by PKC. Activation of PKC causes reduced cells surface expres-
sion of OATP1B1, which is a result of accelerated internalization and
reduced recycling of the transporter protein. Our current study provid-
ed additional insights into the molecular and cellular mechanisms of
phosphorylation-related regulatory effect of OATP family members.
There are ongoing studies in our laboratory to identiﬁed possible PKC
phosphorylation sites of OATP1B1. However, the preliminary results
indicated that simultaneous mutation of putative PKC-related phos-
phorylation sites did not alter OATP1B1 responses to PMA, suggesting
that PKC may affect OATP1B1 internalization indirectly.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.05.011.
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